Brief: LianBio Partner NANOBIOTIX Enters Into License Agreement With Janssen
July 18 (Reuters) - LianBio LIAN.O :
* LIANBIO PARTNER NANOBIOTIX ENTERS INTO LICENSE AGREEMENT
WITH
JANSSEN FOR RADIOENHANCER NBTXR3, WITH LIANBIO RETAINING
DEVELOPMENT AND COMMERCIALIZATION RIGHTS IN GREATER CHINA, SOUTH
KOREA, SINGAPORE AND THAILAND
* LIANBIO - NANOBIOTIX WILL GRANT JANSSEN A WORLDWIDE
LICENSE FOR
CO-DEVELOPMENT AND COMMERCIALIZATION OF NBTXR3
Source text for Eikon: ID:nGNX9t68P9
Further company coverage: LIAN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LianBio
See all newsChina's Zeekr prices US IPO at top of range to raise $441 million (updated)
U.S. STOCKS ON THE MOVE-JetBlue Airways, LPL Financial, Nvidia
U.S. STOCKS ON THE MOVE-Bicycle Therapeutics, Molson Coors, LianBio
LianBio completes strategic review, cuts jobs; shares up
Brief: LianBio Announces Completion Of Strategic Review